



IQWiG Reports – Commission No. A21-75

**Ivacaftor
(combination with ivacaftor/
tezacaftor/elexacaftor; CF,
12 years and older, F508del
mut., RF mut., heterozygous) –
Benefit assessment according to §35a
Social Code Book V¹**

Extract

¹ Translation of Sections 2.1 to 2.5 of the dossier assessment *Ivacaftor (Kombination mit Ivacaftor/Tezacaftor/Elexacaftor; zystische Fibrose, ab 12 Jahre, F508del-Mutation, RF-Mutation, heterozygot) – Nutzenbewertung gemäß § 35a SGB V* (Version 1.0; Status: 30 August 2021). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.

Publishing details

Publisher

Institute for Quality and Efficiency in Health Care

Topic

Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, RF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book V

Commissioning agency

Federal Joint Committee

Commission awarded on

28 May 2021

Internal Commission No.

A21-75

Address of publisher

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Im Mediapark 8
50670 Köln
Germany

Phone: +49 221 35685-0

Fax: +49 221 35685-1

E-mail: berichte@iqwig.de

Internet: www.iqwig.de

Medical and scientific advice

- Thomas O. F. Wagner

IQWiG thanks the medical and scientific advisor for his contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG.

IQWiG employees involved in the dossier assessment

- Ulrike Mikulić
- Ulrich Grouven
- Florina Kerekes
- Marco Knelangen
- Katrin Nink
- Daniela Preukschat
- Min Ripoll
- Sonja Schiller

Keywords: Ivacaftor, Tezacaftor, Elexacaftor, Cystic Fibrosis, Child, Adolescent, Adult, Benefit Assessment, NCT04058353

Table of contents

	Page
List of tables	iv
List of abbreviations	v
2 Benefit assessment	1
2.1 Executive summary of the benefit assessment	1
2.2 Research question	4
2.3 Information retrieval and study pool	5
2.4 Results on added benefit	6
2.5 Probability and extent of added benefit	7
References for English extract	8

List of tables²

	Page
Table 2: Research question of the benefit assessment of ivacaftor + ivacaftor/tezacaftor/elexacaftor	1
Table 3: Ivacaftor + ivacaftor/tezacaftor/elexacaftor – probability and extent of added benefit	3
Table 4: Research question of the benefit assessment of ivacaftor + ivacaftor/tezacaftor/elexacaftor	4
Table 5: Ivacaftor + ivacaftor/tezacaftor/elexacaftor – probability and extent of added benefit	7

² Table numbers start with “2” as numbering follows that of the full dossier assessment.

List of abbreviations

Abbreviation	Meaning
ACT	appropriate comparator therapy
CFTR	cystic fibrosis transmembrane conductance regulator
FEV1	forced expiratory volume in 1 second
G-BA	Gemeinsamer Bundesausschuss (Federal Joint Committee)
IQWiG	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care)
RCT	randomized controlled trial
RF	residual function
SGB	Sozialgesetzbuch (Social Code Book)

2 Benefit assessment

2.1 Executive summary of the benefit assessment

Background

In accordance with § 35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor. The assessment is based on a dossier compiled by the pharmaceutical company (hereinafter referred to as the “company”). The dossier was sent to IQWiG on 28 May 2021.

Research question

The aim of this report is to assess the added benefit of ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor (hereinafter referred to as “ivacaftor + ivacaftor/tezacaftor/elexacaftor”) in comparison with tezacaftor/ivacaftor in combination with ivacaftor (hereinafter referred to as “tezacaftor/ivacaftor + ivacaftor”) as the appropriate comparator therapy (ACT) in cystic fibrosis (CF) patients aged 12 years or older who are heterozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and have a residual function (RF) mutation on the 2nd allele.

The G-BA’s specification of the ACT results in the research question presented in Table 2.

Table 2: Research question of the benefit assessment of ivacaftor + ivacaftor/tezacaftor/elexacaftor

Indication	ACT ^a
CF patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene and have an RFmutation on the 2 nd allele.	Tezacaftor/ivacaftor in combination with ivacaftor
a. Presented is the ACT specified by the G-BA. ACT: appropriate comparator therapy; CFTR: cystic fibrosis transmembrane conductance regulator; G-BA: Federal Joint Committee; RF: residual function	

The company designated tezacaftor/ivacaftor + ivacaftor as the ACT, thus following the G-BA’s specification. The company also reports that the ACT as well as the drug to be assessed were administered in addition to the best available individualized symptomatic treatment. This benefit assessment was conducted in comparison with the ACT specified by the G-BA, tezacaftor/ivacaftor + ivacaftor. Providing additional symptomatic treatment for the patient population is appropriate.

The assessment was conducted by means of patient-relevant outcomes on the basis of the data submitted by the company in the dossier. Randomized controlled trials (RCTs) with a minimum duration of 24 weeks were used for the derivation of added benefit.

Evidence provided by the company***VX18-445-104 study***

In its dossier, the company used the VX18-445-104 study for assessing the added benefit of ivacaftor + ivacaftor/tezacaftor/elexacaftor in comparison with tezacaftor/ivacaftor + ivacaftor. This double-blind RCT included CF patients aged 12 years and older who had a heterozygous F508del mutation in the CFTR gene. The 2nd allele had to have either a gating mutation (including the R117H mutation) or an RF mutation. Depending on the type of mutation, the comparator therapy was either ivacaftor (gating mutations) or tezacaftor/ivacaftor + ivacaftor (residual function mutations). At screening, patients also had to have a forced expiratory volume in 1 second (FEV1) $\geq 40\%$ and $\leq 90\%$ of predicted normal for age, sex, and height. For the present benefit assessment, the subpopulation with an RF mutation on the 2nd allele is relevant.

The study consisted of a 28-day run-in phase, followed by an 8-week treatment phase and a 28-day follow-up observation phase. Following the treatment phase, an open-label extension study was available.

Insufficient study duration

Due to a study duration of only 8 weeks, the VX18-445-104 study submitted by the company is unsuitable for a benefit assessment in the therapeutic indication of CF – a chronic disease requiring lifelong treatment. No conclusions can be drawn on the basis of short-term studies as to whether short-term effects will persist over a longer period. Additionally, it is impossible to record any effects that become apparent only in the longer term, e.g. for pulmonary exacerbations and their consequences or for adverse events.

Overall, studies of at least 24 weeks' duration are necessary to compare benefit and harm in benefit assessments in the therapeutic indication of CF. However, due to the rarity of the mutations to be investigated and the fact that children are affected in this therapeutic indication, the VX18-445-104 study and the corresponding short-term results are presented as supplementary information in the appendix of the dossier assessment. No conclusion on added benefit is derived from them.

Results on added benefit

No suitable data are available for assessing the added benefit of ivacaftor + ivacaftor/tezacaftor/elexacaftor versus the ACT in CF patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene and have an RF mutation on the 2nd allele. Consequently, there is no hint of any added benefit of ivacaftor + ivacaftor/tezacaftor/elexacaftor in comparison with the ACT; an added benefit is therefore not proven.

Probability and extent of added benefit, patient groups with therapeutically important added benefit³

Table 3 shows a summary of the probability and extent of added benefit of ivacaftor + ivacaftor/tezacaftor/elexacaftor.

Table 3: Ivacaftor + ivacaftor/tezacaftor/elexacaftor – probability and extent of added benefit

Indication	ACT ^a	Probability and extent of added benefit
CF patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene and have an RF mutation on the 2 nd allele.	Tezacaftor/ivacaftor in combination with ivacaftor	Added benefit not proven
<p>a. Presented is the ACT specified by the G-BA.</p> <p>ACT: appropriate comparator therapy; CFTR: cystic fibrosis transmembrane conductance regulator; G-BA: Federal Joint Committee; RF: residual function</p>		

The G-BA decides on the added benefit.

³ On the basis of the scientific data analysed, IQWiG draws conclusions on the (added) benefit or harm of an intervention for each patient-relevant outcome. Depending on the number of studies analysed, the certainty of their results, and the direction and statistical significance of treatment effects, conclusions on the probability of (added) benefit or harm are graded into 4 categories: (1) “proof”, (2) “indication”, (3) “hint”, or (4) none of the first 3 categories applies (i.e., no data available or conclusions 1 to 3 cannot be drawn from the available data). The extent of added benefit or harm is graded into 3 categories: (1) major, (2) considerable, (3) minor (in addition, 3 further categories may apply: non-quantifiable extent of added benefit, added benefit not proven, or less benefit). For further details see [1,2].

2.2 Research question

The aim of this report is to assess the added benefit of ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor (hereinafter referred to as “ivacaftor + ivacaftor/tezacaftor/elexacaftor”) in comparison with tezacaftor/ivacaftor in combination with ivacaftor (hereinafter referred to as “tezacaftor/ivacaftor + ivacaftor”) as the ACT in CF patients aged 12 years or older who are heterozygous for the F508del mutation in the CFTR gene and have an RF mutation on the 2nd allele.

The G-BA’s specification of the ACT results in the research question presented in Table 4.

Table 4: Research question of the benefit assessment of ivacaftor + ivacaftor/tezacaftor/elexacaftor

Indication	ACT ^a
CF patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene and have an RF mutation on the 2 nd allele.	Tezacaftor/ivacaftor in combination with ivacaftor
a. Presented is the ACT specified by the G-BA. ACT: appropriate comparator therapy; CFTR: cystic fibrosis transmembrane conductance regulator; G-BA: Federal Joint Committee; RF: residual function	

The company designated tezacaftor/ivacaftor + ivacaftor as the ACT, thus following the G-BA’s specification. The company also reported that the ACT tezacaftor/ivacaftor + ivacaftor as well as the drug to be assessed, ivacaftor + ivacaftor/tezacaftor/elexacaftor, were administered in addition to the best available individualized symptomatic therapy. This benefit assessment was conducted in comparison with the ACT specified by the G-BA, tezacaftor/ivacaftor + ivacaftor. Providing additional symptomatic treatment for the patient population is appropriate.

The assessment was conducted by means of patient-relevant outcomes on the basis of the data submitted by the company in the dossier. RCTs with a minimum duration of 24 weeks were used for the derivation of added benefit. This deviates from the company’s inclusion criteria, which specified a minimum study duration of 8 weeks.

2.3 Information retrieval and study pool

The study pool of the assessment was compiled on the basis of the following information:

Sources cited by the company in the dossier:

- study list on ivacaftor + ivacaftor/tezacaftor/elexacaftor (status: 15 March 2021)
- bibliographic literature search on ivacaftor + ivacaftor/tezacaftor/elexacaftor (most recent search on 15 March 2021)
- search in trial registries / study results databases on ivacaftor + ivacaftor/tezacaftor/elexacaftor (most recent search on 15 March 2021)
- search on the G-BA website for ivacaftor + ivacaftor/tezacaftor/elexacaftor (most recent search on 15 March 2021)

The company's search strategies are documented in the dossier.

To check the completeness of the study pool:

- Search in trial registries for studies on ivacaftor/tezacaftor/elexacaftor (most recent search on 14 March 2021); see Appendix B of the full dossier assessment for the search strategies.

No relevant study was identified from the check.

Evidence provided by the company

VX18-445-104 study

In its dossier, the company used the VX18-445-104 study [3-5] for the assessment of added benefit of ivacaftor + ivacaftor/tezacaftor/elexacaftor in comparison with tezacaftor/ivacaftor + ivacaftor. This double-blind RCT included CF patients aged 12 years and older who had a heterozygous F508del mutation in the CFTR gene. The 2nd allele had to have either a gating mutation (including the R117H mutation) or an RF mutation. Depending on the type of mutation, the comparator therapy was either ivacaftor (gating mutations) or tezacaftor/ivacaftor + ivacaftor (residual function mutations). At screening, patients additionally had to exhibit an FEV1 $\geq 40\%$ and $\leq 90\%$ of predicted normal for age, sex, and height. In the present assessment, the subpopulation with an RF mutation on the 2nd allele corresponds to the therapeutic indication to be assessed. From this subpopulation, 82 patients were randomly allocated to the study's intervention arm and 81 to the control arm.

The study consisted of a 28-day run-in phase, followed by an 8-week treatment phase and a 28-day follow-up observation phase. Following the treatment phase, an open-label extension study was available. During the run-in phase, all patients received tezacaftor/ivacaftor (100/150 mg) in the morning and 150 mg ivacaftor in the evening. While in the control arm, this treatment was continued after randomization, patients in the intervention arm switched to

treatment with ivacaftor/tezacaftor/elexacaftor (150/100/200 mg) in the morning in combination with 150 mg ivacaftor in the evening. The study protocol specified for the individual patients' pretreatment to be continued at a stable dose. However, Module 4 D reveals that individualized adjustments were made in some cases. Treatment with ivacaftor or tezacaftor/ivacaftor was administered in compliance with the Summaries of Product Characteristics [6,7].

The primary outcome of the study was percent change in FEV1 from baseline. Patient-relevant secondary outcomes were symptoms, health-related quality of life, and adverse events.

Insufficient study duration

Due to a study duration of only 8 weeks, the VX18-445-104 study submitted by the company is unsuitable for a benefit assessment in the therapeutic indication of CF – a chronic disease requiring lifelong treatment. The European Medicines Agency (EMA) guideline recommends a minimum duration of 6 months for the investigation of a clinical outcome [8]. IQWiG's General Methods 6.0 also consider long-term studies to be necessary for the benefit assessment of chronic diseases [1]. In the therapeutic indication of CF, short-term studies (with a treatment duration of less than 24 weeks) are unsuitable for the benefit assessment since ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor is a long-term treatment. No conclusions can be drawn on the basis of short-term studies as to whether short term effects persist in the longer term. Additionally, it is impossible to record any effects that become apparent only in the longer term, e.g. for pulmonary exacerbations and their consequences or for adverse events. In Module 4 D, the company justified its inclusion criterion of 8 weeks by arguing that this had been the maximum treatment duration of the only randomized study in the therapeutic indication. The company's rationale was not found plausible.

Overall, studies of at least 24 weeks' duration are necessary to compare benefit and harm in the benefit assessment for the therapeutic indication of CF. However, due to the rarity of the mutations to be investigated and the fact that children are affected, the VX18-445-104 study and the corresponding short-term results are presented as supplementary information in the appendix of the full dossier assessment (see Appendix A of the full dossier assessment). No conclusion on added benefit is derived from them.

2.4 Results on added benefit

No suitable data are available for assessing the added benefit of ivacaftor + ivacaftor/tezacaftor/elexacaftor versus the ACT in CF patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene and have an RF mutation on the 2nd allele. Consequently, there is no hint of an added benefit of ivacaftor + ivacaftor/tezacaftor/elexacaftor in comparison with the ACT; an added benefit is therefore not proven.

2.5 Probability and extent of added benefit

Table 5 presents a summary of the results of the benefit assessment of ivacaftor + ivacaftor/tezacaftor/elexacaftor in comparison with the ACT.

Table 5: Ivacaftor + ivacaftor/tezacaftor/elexacaftor – probability and extent of added benefit

Indication	ACT ^a	Probability and extent of added benefit
CF patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene and have an RF mutation on the 2 nd allele.	Tezacaftor/ivacaftor in combination with ivacaftor	Added benefit not proven
<p>a. Presented is the ACT specified by the G-BA. ACT: appropriate comparator therapy; CFTR: cystic fibrosis transmembrane conductance regulator; G-BA: Federal Joint Committee; RF: residual function</p>		

The assessment described above deviates from that by the company, which derived an indication of considerable added benefit on the basis of the VX18445-104 study.

The G-BA decides on the added benefit.

References for English extract

Please see full dossier assessment for full reference list.

The reference list contains citations provided by the company in which bibliographical information may be missing.

1. Institute for Quality and Efficiency in Health Care. General Methods; Version 6.0 [online]. 2020 [Accessed: 22.03.2021]. URL: https://www.iqwig.de/methoden/general-methods_version-6-0.pdf.
2. Skipka G, Wieseler B, Kaiser T et al. Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs. *Biom J* 2016; 58(1): 43-58. <https://dx.doi.org/10.1002/bimj.201300274>.
3. Vertex Pharmaceuticals. A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) [online]. 2020 [Accessed: 18.06.2021]. URL: <https://ClinicalTrials.gov/show/NCT04058353>.
4. Vertex Pharmaceuticals. Clinical Study Report. Study VX18-445-104. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of Elexacaftor Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes). 21.08.2020. Version 1.0. 2020.
5. Eucfr. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) [online]. 2020 [Accessed: 13.04.2021]. URL: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002835-76/DE>.
6. Vertex Pharmaceuticals. Symkevi 50 mg/75_100 mg/150 mg Filmtabletten [online]. 2020 [Accessed: 16.06.2021]. URL: <https://www.fachinfo.de/>.
7. Vertex Pharmaceuticals. Kalydeco 75 mg Filmtabletten; Kalydeco 150 mg Filmtabletten [online]. 2021 [Accessed: 16.06.2021]. URL: <https://www.fachinfo.de/>.
8. European Medicines Agency. Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis [online]. 2009 [Accessed: 09.07.2021]. URL: https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-development-medicinal-products-treatment-cystic-fibrosis-first-version_en.pdf.

The full report (German version) is published under
<https://www.iqwig.de/en/projects/a21-75.html>.